Ultragenyx Pharmaceutical Inc (MEX:RARE)
MXN 751.98 0 (0%) Market Cap: 65.87 Bil Enterprise Value: 59.05 Bil PE Ratio: 0 PB Ratio: 23.46 GF Score: 70/100

Ultragenyx Pharmaceutical Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 13, 2019 / 04:20PM GMT
Salveen Jaswal Richter
Goldman Sachs Group Inc., Research Division - VP

Good morning. Thanks, everyone, for joining us. I'm Salveen Richter, one of the Biotechnology Analysts at Goldman Sachs, and we're happy to have the Ultragenyx team with us this morning. With us, we have Emil Kakkis, the CEO, President and Founder of this firm.

Questions & Answers

Salveen Jaswal Richter
Goldman Sachs Group Inc., Research Division - VP

So Emil, maybe just to start, at your R&D Day recently, you noted how RARE is now a global commercial company focused on 3 therapeutic areas and developing drugs in 4 therapeutic modalities. Can you just start by walking us through these areas? And how you think about prioritization of different modalities for indication disease?

Emil D. Kakkis
Ultragenyx Pharmaceutical Inc. - President, CEO & Director

Well, we decided to branch out and add gene therapy and mRNA to our original portfolio because there are certain diseases you just can't treat with proteins, additional protein

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot